Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samrat PharmachemBOM:530125 -0.04%63 Days Payable is 55.04 as of Mar. 2026, which is 15% above its 10-year median of 47.83. GuruFocus rates BOM:530125 with a GF Score™ of 63/100 and a GF Value™ of ₹362.79 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,553 Chemicals companies, Samrat Pharmachem ranks worse than 52.99% on this metric.
The historical rank and industry rank for Samrat Pharmachem's Days Payable or its related term are showing as below:
BOM:530125'
s Days Payable Range Over the Past 10 Years
Min: 35.79 Med: 47.83 Max: 65.71
Current: 56.08
During the past 13 years, Samrat Pharmachem's highest Days Payable was 65.71. The lowest was 35.79. And the median was 47.83.
BOM:530125's Days Payable is ranked worse than 52.99% of 1553
companies
in the Chemicals industry
Industry Median: 59.59
vs BOM:530125: 56.08
Samrat Pharmachem's Days Payable
increased
from Mar. 2025 (51.15) to Mar. 2026 (55.04).
It may suggest that Samrat Pharmachemdelayed paying its suppliers.
Samrat Pharmachem Days Payable Related Terms
Samrat Pharmachem Days Payable Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Samrat Pharmachem's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's Days Payable distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Samrat Pharmachem's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samrat Pharmachem (BOM:530125) has a Days Payable of 55.04 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Samrat Pharmachem and its competitors. This is 15% above median its historical median of 47.83. Over the past decade, Samrat Pharmachem's Days Payable has ranged from 35.79 to 65.71. According to the industry distribution chart, Samrat Pharmachem ranks #823 out of 1553 companies in the Chemicals industry, placing it in the top 53%.
Is Samrat Pharmachem's Days Payable too high?
Samrat Pharmachem's current Days Payable of 55.04 is 15% above median its 10-year median of 47.83. Over the past 10 years, this metric has ranged from a low of 35.79 to a high of 65.71. The Chemicals industry median Days Payable is 59.59. Samrat Pharmachem's value of 55.04 is 7.6% below this industry median. Based on the distribution chart, Samrat Pharmachem ranks #823 out of 1553 companies in the Chemicals industry, which is below the industry midpoint. Overall, Samrat Pharmachem has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Days Payable compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #823 out of 1553 companies for Days Payable. This places Samrat Pharmachem in the lower half of its industry. The industry median Days Payable is 59.59. Samrat Pharmachem's value of 55.04 is 7.6% below this benchmark. Historically, Samrat Pharmachem's own Days Payable has ranged from 35.79 to 65.71 over the past decade. While the company's 10-year median is 47.83 vs. the industry median of 59.59, Samrat Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.59, based on 1,553 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Samrat Pharmachem's current Days Payable of 55.04 is 7.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median Days Payable is 59.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current Days Payable is 55.04, which is 15% above median its own 10-year median of 47.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.79, compared to a current price of ₹247.85 — trading 31.7% below its estimated fair value. The current Days Payable is 55.04, which is 15% above median its 10-year median of 47.83 and 7.6% below the Chemicals industry median of 59.59. Samrat Pharmachem's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Days Payable is 55.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹247.85 is trading 31.7% below its estimated GF Value™ of ₹362.79.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
Days Payable: 55.04 (15% above median its 10-year median of 47.83)
GF Value™: ₹362.79 vs. price of ₹247.85 (31.7% below fair value)
Industry Position: 7.6% below the Chemicals median (#823 of 1553)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
63GF Score
Get the complete analysis for BOM:530125
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
